Group 1 - F3 Uranium Corp. has entered into a marketing services agreement with Resource Stock Digest for promotional services effective July 21, 2025 [1][2] - The agreement involves a 3-month advertising and marketing program with a total cash consideration of USD $75,000, payable upon approval by the Exchange [2] - RSD will not receive common shares or options as compensation, and there are no performance factors in the agreement [3] Group 2 - F3 Uranium is focused on uranium exploration, particularly on the high-grade JR Zone at its Patterson Lake North Project in the Western Athabasca Basin [5] - The company holds three properties in the Athabasca Basin: Patterson Lake North, Minto, and Broach, which is known for hosting some of the world's largest high-grade uranium deposits [5]

Vancouver, British Columbia--(Newsfile Corp. - July 11, 2025) - Sanu Gold Corp. (CSE: SANU) (OTCQB: SNGCF) ("Sanu Gold" or the "Company") announces that it has granted an aggregate 11,650,000 incentive stock options to certain officers, directors and other eligible persons of the Company. The options are exercisable, subject to vesting provisions, over a period of five years at a price of $0.25 per share.About Sanu GoldLocated within the Siguiri Basin, a world class gold district that is host to several op ...

Company Strategy & Market Opportunity - Lilly aims to provide freedom from diabetes, eliminate serious health issues caused by obesity, and reduce cardiovascular deaths[10] - The company estimates a significant addressable market of over 170 million patients by 2030 for obesity and related conditions[13] - Outside of the US, the addressable market is expected to be approximately 1 billion patients[15] Orforglipron Development Program - Orforglipron, a GLP-1 small molecule, has a broad development plan including studies for Type 2 Diabetes, obesity, hypertension, and obstructive sleep apnea[20] - In the ACHIEVE-1 trial, all three doses of orforglipron achieved superiority versus placebo in reducing HbA1c levels in patients with Type 2 Diabetes[27] - ACHIEVE-1 trial data showed significant reductions in HbA1c observed as early as 4 weeks, with approximately 3/4 of patients achieving an ADA HbA1c target of less than 7%, and 2/3 reaching HbA1c ≤6.5%[27] - ACHIEVE-1 trial also demonstrated dose-dependent reduction in body weight, with approximately 2/3 of patients achieving ≥5% weight reduction and approximately 1/3 achieving ≥10% weight reduction[30] - Topline results for ATTAIN-1, an orforglipron trial in obesity, are expected in Q3 2025[39] Retatrutide Development Program - Retatrutide is undergoing global development with the TRIUMPH program for obesity and related complications, and the TRANSCEND program for Type 2 Diabetes[41] - Topline results for TRIUMPH-4, a retatrutide trial in knee osteoarthritis pain and overweight or obesity, are expected in Q4 2025[48] Tirzepatide & Early Phase Pipeline - The SURPASS-CVOT trial is designed to evaluate tirzepatide against dulaglutide in patients with established cardiovascular disease[51] - Eloralintide, a selective amylin receptor agonist, showed weight loss up to 11.3% in Phase 1 trials and is well-tolerated with less than 10% incidence of GI side effects[60]

Core Insights - Windfall Geotek has appointed Pierre Daigle to its Advisory Committee, enhancing its leadership in AI-driven mining exploration [1][4] - Daigle brings extensive experience from the Canadian Forces and is recognized for his strategic thinking and problem-solving skills [2][3] - The company is focused on leveraging its AI system for various applications, including landmine detection, and has been developing its proprietary AI analysis and data mining techniques for over 20 years [4][5][6] Company Overview - Windfall Geotek has been utilizing Artificial Intelligence in the mining sector since 2005, positioning itself as a pioneer in AI-driven exploration [5][6] - The company employs a multidisciplinary team of professionals in geophysics, geology, AI, and mathematics to enhance mineral exploration [5] - Windfall's AI algorithms are designed to identify high-potential mineral targets by analyzing public and private datasets [4][6] Strategic Initiatives - The company plans to test its AI system for landmine detection in the coming months, indicating a diversification of its applications beyond mineral exploration [4][6] - CEO Michel Fontaine highlighted Daigle's potential contributions in leveraging his contacts within the Canadian Armed Forces to optimize collaboration on landmine detection projects [3][4]

Not for distribution to United States newswire services or for dissemination in the United States TORONTO, July 10, 2025 (GLOBE NEWSWIRE) -- BULGOLD Inc. (TSXV: ZLTO) (the “Company” or “BULGOLD”) is pleased to announce the closing of its previously announced non-brokered private placement (the "Offering") for gross proceeds of approximately $1,076,720 from the sale of 21,534,407 common shares in the capital of the Company (each, a "Share") at a price of $0.05 per Share (the "Issue Price"). In consideration ...

Prospector Signs Letter of Intent with BeMetals for Option on Savant Gold Project, NW OntarioJuly 10, 2025 7:00 AM EDT | Source: Prospector Metals Corp.Vancouver, British Columbia--(Newsfile Corp. - July 10, 2025) - Prospector Metals Corp. (TSXV: PPP) (OTCQB: PMCOF) (FSE: 1ET) ("Prospector" or the "Company")  is pleased to announce it has entered into a non-binding Letter of Intent ("LOI") with BeMetals (TSXV: BMET) (OTCQB: BMTLF) (FSE: 1OI.F) ("BeMetals" or the "Vendor") to option up to a 100 ...

Group 1 - Avient Corporation plans to release its second quarter 2025 earnings on August 1, 2025, before the market opens [1] - A webcast with a slide presentation will be hosted at 8:00 a.m. Eastern Time on the same day [1] - Participants in the conference call must pre-register to receive the dial-in number and personal PIN for the Q&A session [2] Group 2 - A recording of the webcast and the slide presentation will be available on the company's investor website immediately after the conference call and will remain accessible for one year [3] - Avient Corporation focuses on being an innovator of materials solutions, aiming to help customers succeed while promoting sustainability [4] - The company employs over 9,000 employees globally, leveraging their collective strength to innovate solutions that address customer challenges and capitalize on market opportunities [4]

"We are proud to once again be honored by EcoVadis at the highest distinction for our exceptional sustainability performance," said Jennifer Chittick, senior vice president, Safety, Health and Environment (SH&E); chief sustainability officer. "With EcoVadis setting higher standards year after year, this recognition reflects our team's unwavering commitment to continuous improvement – consistently identifying and implementing opportunities that further advance our sustainability efforts. As we continue our j ...

证券研究报告·行业跟踪周报·医药生物 医药生物行业跟踪周报 2025ADA 重磅数据披露，关注减脂增肌、 Amylin 及口服赛道 增持（维持） [Table_Tag] [Table_Summary] 投资要点 2025 年 06 月 29 日 证券分析师 朱国广 执业证书：S0600520070004 zhugg@dwzq.com.cn 行业走势 -9% -5% -1% 3% 7% 11% 15% 19% 23% 27% 2024/7/1 2024/10/29 2025/2/26 2025/6/26 医药生物 沪深300 相关研究 《科研服务拐点已至，关注皓元医药、 毕得医药、百奥赛图等》 2025-06-23 《线上 618 大促收官+国补持续，关注 国产家用医疗器械放量机遇》 2025-06-21 东吴证券研究所 1 / 27 请务必阅读正文之后的免责声明部分 ◼ 本周、年初至今 A 股医药指数涨幅分别为 1.6%、6.2%，相对沪深 300 的超额收益分别为-0.4%、6.6%；本周、年初至今 H 股生物科技指数涨 跌幅分别为 2.7%、52.7%，相对于恒生科技指数跑赢-1.5%、32.2%； 本周 ...

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" (maintained) [2] Core Insights - The report highlights the emergence of multiple promising weight loss drugs showcased at the 2025 ADA conference, focusing on AMYR and ActRII target drugs, which exhibit excellent clinical data and are expected to become core targets for future weight loss drug development [6][15] - The report emphasizes the potential of oral and ultra-long-acting drugs in the weight loss and glycemic control market, which are anticipated to open new incremental market opportunities [8][31] - The report recommends several pharmaceutical and biotechnology companies as investment targets, including Heng Rui Medicine, East China Medicine, and others across various segments such as CXO, research services, traditional Chinese medicine, raw materials, medical devices, and retail pharmacies [9] Summary by Sections 1. Weight Loss Drug Developments - The 2025 ADA conference showcased several potential pipeline drugs for weight loss, with a focus on AMYR and ActRII target drugs, which are expected to lead future developments in this area [15] - AMYR-targeted drugs, such as eloralintide from Eli Lilly, demonstrated superior efficacy and safety compared to GLP-1 drugs, indicating a promising future for this class of drugs [16][18] - ActRII-targeted drugs, particularly Bimagrumab, showed significant weight loss results, with 100% of weight loss coming from fat, suggesting a new standard for high-quality weight loss therapies [28][29] 2. Oral and Ultra-Long-Acting Drugs - The report identifies oral GLP-1RA drugs as a new trend in the weight loss and glycemic control market, with several companies presenting promising clinical data at the 2025 ADA conference [31][32] - The ultra-long-acting drug Maridebart cafraglutide demonstrated effective weight loss results with extended dosing intervals, enhancing patient compliance and treatment simplicity [33][34] 3. Recommended Investment Targets - The report lists various companies across different segments as recommended investment targets, including pharmaceutical and biotechnology firms, CXO companies, research service providers, traditional Chinese medicine manufacturers, raw material suppliers, medical device companies, and retail pharmacies [9]